Non-Sponsored Content
By: News Feed | Last updated: 6th November 2017 | In: US FDA Onc\Haem Approvals
Article Keywords
Alecensa, alectinib, ALK, FDA, Genentech, Roche
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE
Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
© Copyright 2018 MediPaper Medical Communications Ltd.
MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | Medical Writer Jobs | PMHub
Leave a Reply
Want to join the discussion?Feel free to contribute!